Orforglipron (LY-3502970): Research Overview

Q: How does orforglipron compare to semaglutide for weight loss?

Orforglipron achieved 12.4% weight loss vs semaglutide's 15-20% in trials, but orforglipron is an oral tablet while semaglutide requires weekly injections. For many people, the convenience of taking a daily pill outweighs slightly lower weight loss numbers. It's still in Phase 3 trials (not yet FDA-approved), while semaglutide is established.

Q: Why does orforglipron cause more diarrhea than other GLP-1s?

The file specifically notes that diarrhea is more prevalent with orforglipron than with injectable GLP-1s. This is likely due to its oral bioavailability and how the small molecule formulation affects the GI tract differently than peptide injections. Diarrhea typically improves after the first month as your body adapts.

Oral non-peptide GLP-1 receptor agonist in late-stage trials — a tablet rather than an injection.

Also known as LY3502970 · LY-3502970

Research use onlyStrongest evidence: controlled clinical trialReviewed 19 August 2026

Database References

What is Orforglipron?

First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.

What is Orforglipron researched for?

ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
91% achieved near-normal blood sugar levels versus 42% with placebo.
ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.

How does Orforglipron work?

Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.

Reported targets: GLP-1 receptor

References

ATTAIN-1 Phase 3 Trial
2025
3,127 adults; 72 weeks. 36mg dose achieved 12.4% weight loss (27.3 lbs) versus 2.1% placebo. First oral small-molecule GLP-1 completing Phase 3.
Controlled clinical trial
ATTAIN-2 Phase 3 Trial (Obesity + Type 2 Diabetes)
2025
1,613 adults; 72 weeks. 36mg dose achieved 10.5% weight loss with 72.8% achieving ≥5% weight loss.
Controlled clinical trial
ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes)
2025
559 adults; 40 weeks. All doses significantly reduced HbA1c by 1.3-1.6%; 76.2% achieved HbA1c <7%.
Controlled clinical trial
Phase 2 Obesity Study
2023
272 adults; 36 weeks. Achieved up to 14.7% mean weight reduction at 36 weeks with 45mg dose.
Controlled clinical trial

Common questions

How does orforglipron compare to semaglutide for weight loss?

Orforglipron achieved 12.4% weight loss vs semaglutide's 15-20% in trials, but orforglipron is an oral tablet while semaglutide requires weekly injections. For many people, the convenience of taking a daily pill outweighs slightly lower weight loss numbers. It's still in Phase 3 trials (not yet FDA-approved), while semaglutide is established.

Why does orforglipron cause more diarrhea than other GLP-1s?

The file specifically notes that diarrhea is more prevalent with orforglipron than with injectable GLP-1s. This is likely due to its oral bioavailability and how the small molecule formulation affects the GI tract differently than peptide injections. Diarrhea typically improves after the first month as your body adapts.